| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Forte Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.18 |
| 52 Week High | US$21.25 |
| 52 Week Low | US$4.11 |
| Beta | 1.43 |
| 11 Month Change | -16.73% |
| 3 Month Change | -64.09% |
| 1 Year Change | -64.43% |
| 33 Year Change | -94.95% |
| 5 Year Change | n/a |
| Change since IPO | -99.00% |
Recent News & Updates
Recent updates
We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate
Jul 17
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?
Mar 14Large Forte Biosciences shareholder scolds company board of directors
Aug 24We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely
Aug 17Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan
Aug 16Forte Biosciences large shareholders make demands for company's future
Jul 07We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully
Dec 23Forte Biosciences files for $300M mixed shelf offering
May 28Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?
Mar 13Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?
Jan 19
Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis
Dec 18Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?
Nov 25Forte Biosciences readies equity offering
Oct 28Shareholder Returns
| FBRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -9.5% | -0.7% | -1.6% |
| 1Y | -64.4% | 19.8% | 30.8% |
Return vs Industry: FBRX underperformed the US Biotechs industry which returned 19.8% over the past year.
Return vs Market: FBRX underperformed the US Market which returned 30.8% over the past year.
Price Volatility
| FBRX volatility | |
|---|---|
| FBRX Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: FBRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: FBRX's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 11 | Paul A. Wagner | www.fortebiorx.com |
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Forte Biosciences, Inc. Fundamentals Summary
| FBRX fundamental statistics | |
|---|---|
| Market cap | US$6.10m |
| Earnings (TTM) | -US$35.76m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.2x
P/E RatioIs FBRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FBRX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$35.76m |
| Earnings | -US$35.76m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -24.49 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did FBRX perform over the long term?
See historical performance and comparison